uity (BCVA) at week 36. Secondary outcome measures include the proportion of participants who gain ≥15 letters in BCVA, the proportion of participants with complete resolution of intra- and subretinal fluid, and the proportion of participants with no leakage on fluorescein angiography.
Wet AMD is a leading cause of vision loss in people aged 50 and older. Current treatment options for wet AMD typically require frequent injections into the eye, which can be burdensome for patients. The potential twice-a-year dosing schedule of CLS-AX could offer a more convenient and less invasive treatment option for individuals with this condition.
Clearside Biomedical is dedicated to developing innovative therapies for sight-threatening diseases. The company's SCS Microinjector® technology allows for targeted delivery of drugs to the back of the eye, potentially reducing side effects and improving treatment outcomes.